Certain medications commonly used to treat asthma and COPD can damage the environment and worsen respiratory issues. KYW ...

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

As the prevalence of COPD rises with age ... a cost-effective alternative to pressurized metered-dose inhaler (pMDI) and dry powder inhaler (DPI) devices. DPI device availability is limited ...

Medicare Part D and Medicare Advantage (Part C) plans with drug coverage typically cover inhalers for COPD. But you may still be responsible for a portion of the cost. If you have chronic ...

A new study suggests COPD patients experience improved lung ... in a single once-daily dose in GSK’s Ellipta dry powder inhaler. Novartis says its results support recommendations put forward ...

Treat immediately with an inhaled short-acting beta1-agonist ... After chronic once-daily dry powder inhalation by COPD patients, pharmacokinetic steady state was reached by day 7 with no ...

Many inhalers that are vital for patients with asthma or COPD are associated with societal harms that can worsen the very diseases the products are designed to treat. How can this dilemma be resolved?

Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance inhalers and offers medication management services, according to results ...

The growing incidence of asthma, COPD, and allergies has created a ... Innovations such as dry powder inhalers, soft mist inhalers, and metered-dose inhalers are making it easier for patients ...

a Adapted from Fromer L, Goodwin E, Walsh J. Customizing inhaled therapy to meet the needs of COPD patients. Postgrad Med. 2010; 122:83–93, updated using U.S. Food and Drug Administration.